Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guérin (BCG) vaccine. Issue 4 (22nd January 2021)
- Record Type:
- Journal Article
- Title:
- Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guérin (BCG) vaccine. Issue 4 (22nd January 2021)
- Main Title:
- Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guérin (BCG) vaccine
- Authors:
- Pittet, Laure F.
Tebruegge, Marc
Dutta, Binita
Donath, Susan
Messina, Nicole
Casalaz, Dan
Hanekom, Willem A.
Britton, Warwick J.
Robins-Browne, Roy
Curtis, Nigel
Ritz, Nicole - Abstract:
- Highlights: Infant BCG immunisation induces M. ulcerans -specific immune responses. M. ulcerans - and M. tuberculosis -specific immune responses are qualitatively similar. Magnitude of M. ulcerans -specific immune responses was not influenced by BCG strain. These in-vitro findings support the protective effect observed epidemiologically. Abstract: Background: Bacillus Calmette–Guérin (BCG) vaccine provides partial protection against Buruli ulcer caused by Mycobacterium ulcerans in epidemiological studies. This study aimed to quantify M. ulcerans -specific immune responses induced by BCG immunisation. Methods: Intracellular cytokine analysis of in-vitro experiments done 10 weeks after BCG immunisation in 130 Australian infants randomised to one of three BCG vaccine strains given either at birth (BCG-Denmark, BCG-Japan, or BCG-Russia) or at two months of age (BCG-Denmark). Results: Proportions of polyfunctional CD4 + T-cells were higher in M. ulcerans -stimulated compared to unstimulated control samples. These proportions were not influenced by the vaccine strain or timing of the immunisation. The M. ulcerans -specific immune responses showed similar patterns to those observed in M. tuberculosis -stimulated samples, although they were of lower magnitude. Conclusions: Our data show that BCG immunisation induces M. ulcerans -specific immune responses in infants, likely explaining the cross-protective effect observed in epidemiological studies. (ACTRN12608000227392)
- Is Part Of:
- Vaccine. Volume 39:Issue 4(2021)
- Journal:
- Vaccine
- Issue:
- Volume 39:Issue 4(2021)
- Issue Display:
- Volume 39, Issue 4 (2021)
- Year:
- 2021
- Volume:
- 39
- Issue:
- 4
- Issue Sort Value:
- 2021-0039-0004-0000
- Page Start:
- 652
- Page End:
- 657
- Publication Date:
- 2021-01-22
- Subjects:
- Randomised controlled trial -- Mycobacterium bovis -- Prevention -- Buruli ulcer -- Cross-protection -- Mycolactone
Vaccines -- Periodicals
615.372 - Journal URLs:
- http://www.sciencedirect.com/science/journal/0264410X ↗
http://www.clinicalkey.com/dura/browse/journalIssue/0264410X ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/0264410X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.vaccine.2020.11.045 ↗
- Languages:
- English
- ISSNs:
- 0264-410X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9138.628000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22539.xml